Immunogenicity of a 5‐dose pneumococcal vaccination schedule following allogeneic hematopoietic stem cell transplantation-Reference-Cited by-同舟云学术

Immunogenicity of a 5‐dose pneumococcal vaccination schedule following allogeneic hematopoietic stem cell transplantation

Published:2022-02-17 Issue:5 Volume:97 Page:592-602
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:American J Hematol

Author:

Garcia Garrido Hannah M.¹^ORCID,Haggenburg Sabine²,Schoordijk Marieke C. E.²,Meijer Ellen²,Tanck Michael W. T.³,Hazenberg Mette D.²⁴,Rutten Caroline E.²,Bree Godelieve J.¹,Nur Erfan²⁴,Meek Bob⁵,Grobusch Martin P.¹,Goorhuis Abraham¹

Affiliation:

1. Amsterdam UMC, Centre of Tropical Medicine and Travel Medicine, Department of Infectious Diseases University of Amsterdam, Amsterdam institute for Infection and Immunity Amsterdam The Netherlands

2. Amsterdam UMC, Department of Hematology, Amsterdam Institute for Infection and Immunity Cancer Center Amsterdam Amsterdam The Netherlands

3. Amsterdam UMC, Department of Epidemiology and Data Science University of Amsterdam Amsterdam The Netherlands

4. Department of Hematopoiesis Sanquin Research Amsterdam The Netherlands

5. Department of Medical Microbiology and Immunology St. Antonius Hospital Nieuwegein the Netherlands

Funder

ZonMw

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.26493

Reference35 articles.

1. Incidence of invasive pneumococcal disease in immunocompromised patients: A systematic review and meta-analysis

2. Long-term pneumococcal vaccine immunogenicity following allogeneic hematopoietic stem cell transplantation

3. Vaccination of haemopoietic stem cell transplant recipients: guidelines of the 2017 European Conference on Infections in Leukaemia (ECIL 7)

4. Executive Summary: 2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host

5. Immunogenicity, Safety, and Tolerability of 13-Valent Pneumococcal Conjugate Vaccine Followed by 23-Valent Pneumococcal Polysaccharide Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant Aged ≥2 Years: An Open-Label Study

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Vaccination of Adults With Cancer: ASCO Guideline;Journal of Clinical Oncology;2024-05-10

2. Invasive pneumococcal serotype 3 infection following pneumococcal vaccination in a hematopoietic stem cell transplant patient: A case report;IDCases;2024

3. Pneumococcal Vaccine for Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices, United States, 2023;MMWR. Recommendations and Reports;2023-09-08

4. Vaccine schedule recommendations and updates for patients with hematologic malignancy post‐hematopoietic cell transplant or CAR T‐cell therapy;Transplant Infectious Disease;2023-07-29

5. Immunogenicity of the 13-Valent Pneumococcal Conjugated Vaccine Followed by the 23-Valent Polysaccharide Vaccine in Chronic Lymphocytic Leukemia;Vaccines;2023-07-04